 At the same time points the International Cooperative Ataxia Rating Scale ICARS for pharmacological assessment of the cerebellar syndrome will be administered to the two groups riluzole and placebo of patients. To guarantee the evaluation of the results in blind conditions, the neurologists who will evaluate the ICARS scores will be different from those who will deal with randomisation and follow-up of patients. 